Despite more than three decades of intensive effort, no effective pharmacological inhibitors
of the RAS oncoproteins have reached the clinic, prompting the widely held perception that …

Renal cancer management is challenging from diagnosis to treatment and follow-up. In
cases of small renal masses and cystic lesions the differential diagnosis of benign or …

Inactive von Hippel-Lindau (VHL) is linked to metabolic reprogramming and plays pivotal
roles in the pathogenesis of clear cell renal cell carcinoma (ccRCC). Here, we identify a …

Mutational signature analysis is commonly performed in cancer genomic studies. Here, we
present SigProfilerExtractor, an automated tool for de novo extraction of mutational …

To elucidate the deregulated functional modules that drive clear cell renal cell carcinoma
(ccRCC), we performed comprehensive genomic, epigenomic, transcriptomic, proteomic …

Mutational hotspots indicate selective pressure across a population of tumor samples, but
their prevalence within and across cancer types is incompletely characterized. An approach …

All cancers are caused by somatic mutations; however, understanding of the biological
processes generating these mutations is limited. The catalogue of somatic mutations from a …

Genetic changes underlying clear cell renal cell carcinoma (ccRCC) include alterations in
genes controlling cellular oxygen sensing (for example, VHL) and the maintenance of …

Clear cell renal carcinomas (ccRCCs) can display intratumor heterogeneity (ITH). We
applied multiregion exome sequencing (M-seq) to resolve the genetic architecture and …

Abstract Since the Von Hippel–Lindau (VHL) disease tumour suppressor gene VHL was
identified in 1993 as the genetic basis for a rare disorder, it has proved to be of wide medical …